Author:
O'Donnell A,Padhani A,Hayes C,Kakkar A J,Leach M,Trigo J M,Scurr M,Raynaud F,Phillips S,Aherne W,Hardcastle A,Workman P,Hannah A,Judson I
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin Jr WG (2002) Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 109(9): 1745–1751
2. Antonian L, Zhang H, Yang C, Wagner G, Shawver LK, Shet M, Ogilvie B, Madan A, Parkinson A (2000) Biotransformation of the anti-angiogenic compound SU5416. Drug Metab Dispos 28(12): 1505–1512
3. Choyke PL, Dwyer AJ, Knopp MV (2003) Functional tumour imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17: 509–520
4. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel CL, Remick S (2005) A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 55(3): 295–300
5. Cropp G, Rosen L, Mulay M, Langecker P, Hannah A (1999) Pharmacokinetics and pharmacodynamics of SU5416 a phase I, dose escalating trial in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 19: 161a
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献